"Somatostatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal.
| Descriptor ID |
D013004
|
| MeSH Number(s) |
D06.472.699.327.700.875 D06.472.699.587.780 D12.644.400.400.700.875 D12.644.548.365.700.875 D12.644.548.586.780 D12.776.631.650.405.700.875
|
| Concept/Terms |
Somatostatin- Somatostatin
- SRIH-14
- Somatotropin Release-Inhibiting Factor
- Somatotropin Release Inhibiting Factor
- Cyclic Somatostatin
- Somatostatin-14
- Somatostatin 14
- Somatotropin Release-Inhibiting Hormone
- Somatotropin Release Inhibiting Hormone
- Somatostatin, Cyclic
|
Below are MeSH descriptors whose meaning is more general than "Somatostatin".
Below are MeSH descriptors whose meaning is more specific than "Somatostatin".
This graph shows the total number of publications written about "Somatostatin" by people in this website by year, and whether "Somatostatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Somatostatin" by people in Profiles.
-
Dalton EC, Johns MS, Rhodes L, Merritt WT, Petrelli NJ, Tiesi GJ. Meta-Analysis on the Effect of Pasireotide for Prevention of Postoperative Pancreatic Fistula. Am Surg. 2020 Dec; 86(12):1728-1735.
-
Dalton EC, Johns MS, Rhodes L, Merritt WT, Petrelli NJ, Tiesi GG. Meta-analysis on the Effect of Pasireotide for Prevention of Postoperative Pancreatic Fistula. Am Surg. 2020 May; 86(5):429-436.
-
Yeo CJ. Invited Commentary: Pasireotide and the Prevention of Pancreatic Fistula After Pancreatectomy: "The Continued Search for Harry Potter's Liquid Luck". Ann Surg. 2017 01; 265(1):17-19.
-
Volk DW, Chitrapu A, Edelson JR, Lewis DA. Chemokine receptors and cortical interneuron dysfunction in schizophrenia. Schizophr Res. 2015 Sep; 167(1-3):12-7.
-
Lewis MA, Thompson GB, Young WF. Preoperative assessment of the pancreas in multiple endocrine neoplasia type 1. World J Surg. 2012 Jun; 36(6):1375-81.
-
Milan SA, Yeo CJ. Neuroendocrine tumors of the pancreas. Curr Opin Oncol. 2012 Jan; 24(1):46-55.
-
Dun SL, Brailoiu GC, Tica AA, Yang J, Chang JK, Brailoiu E, Dun NJ. Neuronostatin is co-expressed with somatostatin and mobilizes calcium in cultured rat hypothalamic neurons. Neuroscience. 2010 Mar 17; 166(2):455-63.
-
Weiner RE, Thakur ML. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot. 2002 Nov; 57(5):749-63.
-
Thakur ML, Kolan H, Li J, Wiaderkiewicz R, Pallela VR, Duggaraju R, Schally AV. Radiolabeled somatostatin analogs in prostate cancer. Nucl Med Biol. 1997 Jan; 24(1):105-13.
-
Surmeier DJ, Mermelstein PG, Goldowitz D. The weaver mutation of GIRK2 results in a loss of inwardly rectifying K+ current in cerebellar granule cells. Proc Natl Acad Sci U S A. 1996 Oct 01; 93(20):11191-5.